Cytomegalovirus may cause anemia in patients with kidney disease
4/14/2014
A virus that is present in most people in a latent state may induce or exacerbate anemia in patients with kidney disease, according to a study appearing in an upcoming issue of the Journal of the...
Growth factor receptors identified that may prompt the spread of lung cancer
4/13/2014
Two cell surface receptors might be responsible for the most common form of lung cancer spreading to other parts of the body, according to a study led by the Translational Genomics Research Institute...
Commission suggests improvements to cancer care in China, India and Russia
4/12/2014
The Lancet Oncology publish the findings of a special commission formed to analyze the quality of cancer care in three large countries that present major health care challenges.
Copper starvation could be promising treatment for some cancers
4/11/2014
Researchers who found some cancers caused by a mutation in the BRAF gene need copper to fuel tumor growth, suggest they may be treatable with drugs that block copper absorption.
Moffitt Cancer Center begins Phase I clinical trial of new immunotherapy
4/11/2014
Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design.
Biogen Idec and Swedish Orphan Biovitrum AB (Sobi) have released positive top-line results of the Kids A-LONG Phase 3 clinical study that evaluated the safety and efficacy of Eloctate(TM), an...
A high-fat diet can increase risk of certain types of breast cancer
4/11/2014
High total and saturated fat intake were associated with greater risk of estrogen receptor- and progesterone receptor-positive (ER+PR+) breast cancer (BC), and human epidermal growth factor 2...
Newly invented hydrogel may help 'nuanced' healing of surgical wounds
4/11/2014
Synthetic collagen invented at Rice University may help wounds heal by directing the natural clotting of blood.
Dabrafenib assessed in comparison with vemurafenib: no added benefit
4/11/2014
Results from indirect comparison did not allow any reliable conclusionsDabrafenib (trade name: Tafinlar) has been approved since August 2013 for the treatment of advanced melanoma.
Treatment-resistant leukemias may be vulnerable to experimental drug
4/11/2014
Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed...